Analysts See $-0.14 EPS for OncoSec Medical Incorporated (ONCS) as of June, 7

May 17, 2018 - By Joseph Norton

OncoSec Medical Incorporated (NASDAQ:ONCS) Corporate Logo

On June, 7 OncoSec Medical Incorporated (NASDAQ:ONCS)’s earnings report is awaited by WallStreet, Zacks reports. This year’s EPS analyst estimate is awaited to be $-0.14. That is 36.36 % up compareed to $-0.22 EPS for last year. Last quarter $-0.24 EPS was reported. Analysts predicts -41.67 % EPS growth this quarter. The stock increased 4.09% or $0.07 during the last trading session, hitting $1.78.OncoSec Medical Incorporated is uptrending after having risen 44.62% since May 17, 2017. ONCS has 1.54M volume or 30.90% up from normal. The stock outperformed the S&P 500 by 33.07%.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States.The firm is valued at $91.64 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer.Currently it has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

Another two news for OncoSec Medical Incorporated (NASDAQ:ONCS) were recently posted by: on April 18, 2018 with title “OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner”. The other‘s article was titled “Oncosec Medical (ONCS) Expands Relationship with Merck (MRK); Announces Clinical Collaboration to Evaluate …” and posted on May 08, 2018.

OncoSec Medical Incorporated (NASDAQ:ONCS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.